{"id":"W2590379099","doi":"10.1200/jco.2015.33.28_suppl.155","title":"Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- <i>BRCA</i>-associated locally advanced or metastatic breast cancer (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Veliparib; Medicine; PARP inhibitor; Carboplatin; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; BRCA mutation; Cancer; Placebo; Chemotherapy; Phases of clinical research; Olaparib; Pathology; Cisplatin; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002771243,0.003187628,0.00422158,0.0005871304,0.0008387875,0.001992322,0.00176657,0.002836421,0.01243511],"category_scores_gemma":[0.002398599,0.00134786,0.001991766,0.0006777478,0.002258799,0.001964119,0.0006171862,0.006039593,0.003036886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001391703,"about_ca_system_score_gemma":0.002407399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001555395,"about_ca_topic_score_gemma":0.003458357,"domain_scores_codex":[0.9990947,0.0004030588,0.00004802484,0.0002337391,0.00005679405,0.0001636976],"domain_scores_gemma":[0.9984543,0.0003185448,0.0003140393,0.0001568161,0.0001218242,0.0006344228],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9855973,0.007986424,0.0001662054,0.0002613858,0.0003395806,0.00002214456,0.00002561676,0.0001422729,0.001267933,0.00006953555,0.0008064896,0.003315042],"study_design_scores_gemma":[0.9750704,0.02379167,0.0003092679,0.00001281517,0.0001135331,0.0000139566,0.00001005582,0.0001560975,0.0001302718,0.00009174869,0.0002930738,0.000006901598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9465258,0.005466252,0.002038099,0.002326159,0.003105194,0.02858157,0.005025615,0.0005526442,0.006378802],"genre_scores_gemma":[0.9503285,0.003276087,0.003809782,0.003551848,0.001082373,0.02568075,0.003722843,0.00008933479,0.008458427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01243511,"threshold_uncertainty_score":0.04159957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1007971988423763,"score_gpt":0.4784896302964782,"score_spread":0.3776924314541018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}